Benralizumab
Phase 3UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Asthma, Exercise-Induced
Conditions
Asthma, Exercise-Induced
Trial Timeline
Dec 1, 2017 → Apr 1, 2020
NCT ID
NCT03327701About Benralizumab
Benralizumab is a phase 3 stage product being developed by AstraZeneca for Asthma, Exercise-Induced. The current trial status is unknown. This product is registered under clinical trial identifier NCT03327701. Target conditions include Asthma, Exercise-Induced.
What happened to similar drugs?
20 of 20 similar drugs in Asthma, Exercise-Induced were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (18)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07444567 | Phase 3 | Recruiting |
| NCT07214753 | Pre-clinical | Recruiting |
| NCT06512883 | Phase 3 | Recruiting |
| NCT06465485 | Phase 3 | Active |
| NCT05273359 | Phase 2 | UNKNOWN |
| NCT05384938 | Approved | Completed |
| NCT05932849 | Pre-clinical | Completed |
| NCT04305405 | Phase 3 | Completed |
| NCT04102800 | Approved | Completed |
| NCT03928262 | Phase 1 | Completed |
| NCT03557307 | Phase 3 | Completed |
| NCT03327701 | Phase 3 | UNKNOWN |
| NCT03010436 | Phase 2 | UNKNOWN |
| NCT02918071 | Phase 3 | Completed |
| NCT02869438 | Phase 3 | Completed |
| NCT02821416 | Phase 3 | Completed |
| NCT02417961 | Phase 3 | Completed |
| NCT02130882 | Phase 2/3 | UNKNOWN |
Competing Products
20 competing products in Asthma, Exercise-Induced